Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450626 | 0.80 | POLB (0.59) | LMNARAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4817931 | 0.79 | LMNA (1.00) | LMNASTAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12857990 | 0.78 | STAT3 (0.73) | LMNASTAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6448938 | 0.78 | POLB (0.61) | RAB9ANPC1SMN1; SMN2POLBGAA | |
| SCHEMBL11389900 | 0.77 | ALDH1A1 (0.60) | LMNARAB9ASMN1; SMN2POLBGAA | |
| SCHEMBL23084665 | 0.77 | STAT3 (0.72) | LMNASTAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6449818 | 0.76 | RAB9A (0.61) | LMNARAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL6453448 | 0.76 | NPC1 (1.00) | LMNASTAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2666946 | 0.76 | STAT3 (0.71) | LMNASTAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6449064 | 0.76 | NPC1 (0.66) | LMNASTAT3RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | LMNA 2406/4885STAT3 1567/4885RAB9A 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.